# 義大利反壟斷機構表示已對藥廠Biogen Italia及其母公司Biogen展開調查，指控其涉嫌濫用壟斷地位。

*biotech · news · 2026-05-27 · MarketScreener*

## Key points

- 義大利反壟斷機構正在調查Biogen Italia及Biogen是否濫用市場支配地位。
- 調查涉及試圖排除Sandoz銷售基於納他珠單抗的多發性硬化症藥物。
- 義大利監管機構與財政警察已對Biogen義大利辦公室進行檢查。
- Biogen尚未就調查發表聲明或評論。

MILAN, May 27 (Reuters) - Italy's antitrust authority said on Wednesday it had opened an investigation into drug maker Biogen Italia and its parent Biogen over alleged abuse of dominant position. The two companies allegedly aimed at excluding rival Sandoz from offering multiple sclerosis drugs, based on active ingredient natalizumab, the regulator said in a statement. The watchdog carried out inspections at Biogen's Italian offices, assisted by Italy's finance police, it added. Biogen was not immediately available for comment. (Reporting by Cristina Carlevaro, editing by Giulia Segreti)

**Companies:** Biogen Italia, Biogen
**Countries:** 義大利

[Read the full story on MarketScreener](https://www.marketscreener.com/news/italy-s-antitrust-regulator-opens-probe-into-us-biogen-over-alleged-dominant-position-ce7f5ad2de88f224)

---

Canonical: https://newsio.io/zh-TW/n/d9ca70fa-f4f1-494b-b049-475be0124604/biogen-italiabiogensandoz
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works